Browsing by Author "Bello, Aminu K."

Now showing 1 - 3 of 3
  • Thumbnail Image
    ItemOpen Access
    Can Virtual Care Support the Outpatient Management of Patients Treated with Chronic Hemodialysis? Lessons from Designing and Testing a Virtual Visit Program in Alberta
    (2020-05-25) Lunney, Meaghan; Tonelli, Marcello; Bello, Aminu K.; Rabi, Doreen M.; Thomas, Chandra M.
    Many people have difficulty accessing healthcare. Virtual care allows patients and providers to interact using information and communication technologies, which may mitigate inconvenience associated with in-person appointments and potentially barriers to accessing care. Virtual appointments using videoconferencing technology (herein named virtual visits) have become a widely used form of virtual care due to its convenience and accessibility for patients. People with kidney failure receiving dialysis require frequent and ongoing care from multiple healthcare providers and there is a significant potential for virtual visits in this setting. However, the current interest among relevant stakeholders and the optimal delivery processes for outpatient virtual kidney failure management, to our knowledge, are unknown. Our program of study involved: a systematic review of studies exploring the use of virtual care in kidney failure management; interviews with patients and healthcare providers about virtual visit design; and a pilot test of the virtual visit intervention at a kidney clinic to learn about the user experience and identify workflow and resource requirements needed for delivering virtual visits. We hope this research will help inform future decision-making around virtual visit services in our kidney program. Our review found a gap in evidence related to virtual visits for outpatient kidney failure management. Interviews with patients, nurses, and nephrologists confirmed an interest in virtual visits, mainly as they are more convenient for patients and may increase access to care. Further, these stakeholders provided virtual visit recommendations that helped inform the intervention design. Our pilot study found that patients and nephrologists were highly satisfied with the virtual visit intervention. Both groups stated they would use virtual visits again and recommend them to their peers. Most patients used their own devices (computers, tablets, smartphones), but the clinic did not have sufficient hardware for virtual visits. Workflow considerations identified through our study included: using electronic medical records and coordinating with dialysis nurses to collect health information needed for the virtual visit; providing training and technical support to patients; and using a combination of in-person visits and virtual visits as appropriate. Further, clarity around medical-legal matters, platform governance, and future remuneration policies is needed. Overall, our research suggests virtual visits are appropriate for outpatient kidney failure care and warranted by patients, nurses, and nephrologists, given the right circumstances. We identified process and workflow considerations for facilitating virtual visit in outpatient kidney clinics. Lastly, we identified barriers, mainly related to information technology infrastructure and governance, that will need to be addressed to fully capitalize on the benefits of virtual care.
  • Thumbnail Image
    ItemOpen Access
    Global variations in funding and use of hemodialysis accesses: an international report using the ISN Global Kidney Health Atlas
    (2024-05-08) Ghimire, Anukul; Shah, Samveg; Chauhan, Utkarsh; Ibrahim, Kwaifa S.; Jindal, Kailash; Kazancioglu, Rumeyza; Luyckx, Valerie A.; MacRae, Jennifer M.; Olanrewaju, Timothy O.; Quinn, Robert R.; Ravani, Pietro; Shah, Nikhil; Thompson, Stephanie; Tungsanga, Somkanya; Vachharanjani, Tushar; Arruebo, Silvia; Caskey, Fergus J.; Damster, Sandrine; Donner, Jo-Ann; Jha, Vivekanand; Levin, Adeera; Malik, Charu; Nangaku, Masaomi; Saad, Syed; Tonelli, Marcello; Ye, Feng; Okpechi, Ikechi G.; Bello, Aminu K.; Johnson, David W.
    Abstract Background There is a lack of contemporary data describing global variations in vascular access for hemodialysis (HD). We used the third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) to highlight differences in funding and availability of hemodialysis accesses used for initiating HD across world regions. Methods Survey questions were directed at understanding the funding modules for obtaining vascular access and types of accesses used to initiate dialysis. An electronic survey was sent to national and regional key stakeholders affiliated with the ISN between June and September 2022. Countries that participated in the survey were categorized based on World Bank Income Classification (low-, lower-middle, upper-middle, and high-income) and by their regional affiliation with the ISN. Results Data on types of vascular access were available from 160 countries. Respondents from 35 countries (22% of surveyed countries) reported that > 50% of patients started HD with an arteriovenous fistula or graft (AVF or AVG). These rates were higher in Western Europe (n = 14; 64%), North & East Asia (n = 4; 67%), and among high-income countries (n = 24; 38%). The rates of > 50% of patients starting HD with a tunneled dialysis catheter were highest in North America & Caribbean region (n = 7; 58%) and lowest in South Asia and Newly Independent States and Russia (n = 0 in both regions). Respondents from 50% (n = 9) of low-income countries reported that > 75% of patients started HD using a temporary catheter, with the highest rates in Africa (n = 30; 75%) and Latin America (n = 14; 67%). Funding for the creation of vascular access was often through public funding and free at the point of delivery in high-income countries (n = 42; 67% for AVF/AVG, n = 44; 70% for central venous catheters). In low-income countries, private and out of pocket funding was reported as being more common (n = 8; 40% for AVF/AVG, n = 5; 25% for central venous catheters). Conclusions High income countries exhibit variation in the use of AVF/AVG and tunneled catheters. In low-income countries, there is a higher use of temporary dialysis catheters and private funding models for access creation.
  • Thumbnail Image
    ItemOpen Access
    Prevalence of polypharmacy and associated adverse health outcomes in adult patients with chronic kidney disease: protocol for a systematic review and meta-analysis
    (2021-07-04) Okpechi, Ikechi G.; Tinwala, Mohammed M.; Muneer, Shezel; Zaidi, Deenaz; Ye, Feng; Hamonic, Laura N.; Khan, Maryam; Sultana, Naima; Brimble, Scott; Grill, Allan; Klarenbach, Scott; Lindeman, Cliff; Molnar, Amber; Nitsch, Dorothea; Ronksley, Paul; Shojai, Soroush; Soos, Boglarka; Tangri, Navdeep; Thompson, Stephanie; Tuot, Delphine; Drummond, Neil; Mangin, Dee; Bello, Aminu K.
    Abstract Background Polypharmacy, often defined as the concomitant use of ≥ 5 medications, has been identified as a significant global public health threat. Aging and multimorbidity are key drivers of polypharmacy and have been linked to a broad range of adverse health outcomes and mortality. Patients with chronic kidney disease (CKD) are particularly at high risk of polypharmacy and use of potentially inappropriate medications given the numerous risk factors and complications associated with CKD. The aim of this systematic review will be to assess the prevalence of polypharmacy among adult patients with CKD, and the potential association between polypharmacy and adverse health outcomes within this population. Methods/design We will search empirical databases such as MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, and PsycINFO and grey literature from inception onwards (with no language restrictions) for observational studies (e.g., cross-sectional or cohort studies) reporting the prevalence of polypharmacy in adult patients with CKD (all stages including dialysis). Two reviewers will independently screen all citations, full-text articles, and extract data. Potential conflicts will be resolved through discussion. The study methodological quality will be appraised using an appropriate tool. The primary outcome will be the prevalence of polypharmacy. Secondary outcomes will include any adverse health outcomes (e.g., worsening kidney function) in association with polypharmacy. If appropriate, we will conduct random effects meta-analysis of observational data to summarize the pooled prevalence of polypharmacy and the associations between polypharmacy and adverse outcomes. Statistical heterogeneity will be estimated using Cochran’s Q and I2 index. Additional analyses will be conducted to explore the potential sources of heterogeneity (e.g., sex, kidney replacement therapy, multimorbidity). Discussion Given that polypharmacy is a major and a growing public health issue, our findings will highlight the prevalence of polypharmacy, hazards associated with it, and medication thresholds associated with adverse outcomes in patients with CKD. Our study will also draw attention to the prognostic importance of improving medication practices as a key priority area to help minimize the use of inappropriate medications in patients with CKD. Systematic review registration PROSPERO registration number: [ CRD42020206514 ].